Article Information
History
- September 29, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maria Krutikov, MRCP1,*,
- Tom Palmer, MSc2,
- Gokhan Tut, PhD4,
- Christopher Fuller, MSc1,
- Borscha Azmi, MSc1,
- Rebecca Giddings, MFPH1,
- Madhumita Shrotri, MFPH1,
- Nayandeep Kaur, MSc4,
- Panagiota Sylla, MSc4,
- Tara Lancaster, PhD4,
- Aidan Irwin-Singer, MA6,
- Andrew Hayward, MD3,5,
- Paul Moss, PhD4,
- Andrew Copas, PhD2 and
- Laura Shallcross, PhD1
- 1UCL Institute of Health Informatics, London, UK
- 2UCL Institute for Global Health, London, UK
- 3UCL Institute of Epidemiology & Health Care
- 4Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
- 5Health Data Research UK
- 6Department of Health and Social Care, London, UK
- ↵*Correspondence to: Dr Maria Krutikov MRCP; m.krutikov{at}ucl.ac.uk, Institute of Health Informatics, University College London
Posted September 29, 2021.
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study
